Compare KE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | ALT |
|---|---|---|
| Founded | 1961 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.2M | 573.8M |
| IPO Year | 2014 | 2005 |
| Metric | KE | ALT |
|---|---|---|
| Price | $26.17 | $3.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $17.67 |
| AVG Volume (30 Days) | 206.6K | ★ 4.0M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.18 | 25.37 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $1,431,378,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $22.16 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $21.60 | $2.56 |
| 52 Week High | $33.19 | $6.44 |
| Indicator | KE | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 57.93 |
| Support Level | $23.42 | $3.18 |
| Resistance Level | $26.85 | $3.32 |
| Average True Range (ATR) | 0.70 | 0.15 |
| MACD | 0.17 | 0.02 |
| Stochastic Oscillator | 83.15 | 56.68 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.